ReAnima will try to restore brain function of the dead
Research in medical science often comes to certain ethical barriers. Especially today, when a lot of research is done around the very origin of a human being. On the other hand, there are companies like Bioquark, interested in the final moments of human life. Bioquark’s project named ReAnima has recently been granted an approval from Institutional Review Board in the US to conduct its first trial. Its name – Non-randomized, open-labeled, interventional, single group, proof of concept study with multi-modality approach in cases of brain death due to traumatic brain injury having diffuse axonal injury. Its aim – to test if it is possible to reverse brain death.
Each year, for over 60 million people, brain death is the final state from which they never recover. Concept studies have shown that it should be possible to alter this state via medical intervention. ReAnima’s first trial will be carried out in India, on 20 subjects in the state of brain death. Already pronounced dead, as the brain ceased to function irreparably, the subjects’ other bodily functions will be kept operating via life support. A combination of approaches will be applied, varying from stem cell injections, peptides cocktails, lasers and other nerve stimulation techniques. The task of these is to restart the normal, or even limited, function of the brain. Dr. Sergei Paylian, Founder, President, and Chief Science Officer of Bioquark Inc.:
Dr. Sergei Paylian
“Through our study, we will gain unique insights into the state of human brain death, which will have important connections to future therapeutic development for other severe disorders of consciousness, such as coma, and the vegetative and minimally conscious states, as well as a range of degenerative CNS conditions, including Alzheimer’s and Parkinson’s disease.”
Exploration in this field was largely fueled by observing the capacity of amphibians, planarians, and certain fish, which can rebuild large parts of their brain after suffering a brain injury. This study will be the first of its kind, so it is necessary to mention its importance even now, when it did not yet produce any results. ReAnima is still looking for its subjects, but it also has plans for further research. At least five more projects are planned by the company, however, details of these remain unknown.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Tracking
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.